Clinical Trials – Head and Neck Cancer

Clinical Trials – Head and Neck Cancer

Clinical Trials – Head and Neck Cancer

1. CTSU E1305
Recurrent or Metastatic Disease
Eligibility: SCC of H&N, any primary; recurrent and incurable by surgery or metastatic; no prior chemo or bio therapy for rec/met dz; 1 prior regimen of induction or adj chem and/or RT with curative intent allowed; must be > 6 months since last chemo and/or RT; palliative RT to H&N allowed but must be > 8 wks since last dose; no prior Bev; no brain mets; Rx: physician choice of Docetaxel/Cisplatin or Cisplatin/5FU; pt then randomized to chemo +/- bevacizumab. (BEVACIZUMAB SUPPLIED)

1. RTOG 0920
SCC (and variants) of the Oral Cavity, Oropharynx or Larynx
Eligibility: Clinical stage T1, N1-2 or T2-3, N0-2, M0; gross total resection of primary with curative intent; must enroll within 7 weeks post-op; tumor must have 1 or more intermediate risk factors (see protocol p17 section 3.1.3.1- 3.1.3.6); performance status 0-1; Rx: IMRT alone versus IMRT + Cetuximab (CETUXIMAB SUPPLIED) IMRT credentialling required- see protocol p. 20, section 5.3

Abbreviations:
CALGB = Cancer and Leukemia Group B
CTSU = Cancer Trials Support Unit
ECOG = Eastern Cooperative Oncology Group
NCI = National Cancer Institute
NSABP = National Surgical Adjunct Breast and Bowel Project
RTOG = Radiation Therapy Oncology Group
SCUSF = SunCoast CCOP Research Base
SWOG = Southwest Oncology Group
Top ↑
© 2011 Bay Area Cancer Physicians